Open-label study of s-citalopram therapy of chronic fatigue syndrome and co-morbid major depressive disorder

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 32, Issue 1, 2008, Pages 100-106

  Amsterdam, Jay D ^a   Shults, Justine ^a   Rutherford, Nancy ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Chronic fatigue syndrome (CFS); Fatigue; Major Depressive Disorder; s citalopram; Selective serotonin reuptake inhibitor (SSRI)

Indexed keywords

CITALOPRAM; ZALEPLON; ZOLPIDEM;

ADULT; AGED; ARTICLE; ATTENTION DISTURBANCE; BECK DEPRESSION INVENTORY; CHRONIC FATIGUE SYNDROME; CLINICAL TRIAL; COMORBIDITY; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HAMILTON SCALE; HEADACHE; HUMAN; INSOMNIA; LABORATORY TEST; LIBIDO DISORDER; MAJOR DEPRESSION; MALAISE; MALE; MEMORY DISORDER; MENTAL CONCENTRATION; MENTAL PATIENT; NERVOUSNESS; OPEN STUDY; QUESTIONNAIRE; RATING SCALE; RESTLESSNESS; SIDE EFFECT; SYMPTOM; TREATMENT DURATION; TREATMENT OUTCOME; VISUAL ANALOG SCALE; VITAL SIGN;

ADULT; AGED; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CITALOPRAM; DEPRESSIVE DISORDER, MAJOR; DRUG EVALUATION; FATIGUE SYNDROME, CHRONIC; FEMALE; HUMANS; MALE; MIDDLE AGED; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 38349074503     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2007.07.019     Document Type: Article

References (68)

1. Alnigenis M.N.Y., and Barland P. Fibromyalgia syndrome and serotonin. Clin Exp Rheumatol 19 (2001) 205-210
2. American Psychiatric Association. Diagnostic and Statistical Manual-Version IV TR, Washington, DC (2000)
3. Amsterdam J.D., Henle W., Winokur A., Wolkowitz O., Pickar D., and Paul S.M. Serum antibodies to Epstein-Barr virus in patients with major depressive disorder. Am J Psychiatry 143 (1986) 1593-1596
4. Anderberg U.M., Marteinsdottir I., and von Knorring L. Citalopram in patients with fibromyalgia-a randomized, double blind, placebo-controlled study. Eur J Pain 4 (2000) 27-35
5. Ansari A. Efficacy of new antidepressants in the treatment of chronic pain: a review of current literature. Harv Rev Psychiatry 7 (2000) 257-277
6. Arnold L.M., Keck P.E., and Welge J.A. Antidepressant treatment of fibromyalgia. A meta-analysis and review. Psychosomatics 41 (2000) 104-113
7. Arnold L.M., Hess E.V., Hudson J.I., Welg J.A., Berno S.E., and Keck P.E. A randomized, placebo-controlled, double-blind, flexible dose study of fluoxetine in the treatment of women with fibromyalgia. Am J Med 112 (2002) 191-197
8. Bakheit A.M.O., Behan P.O., Dinan T.G., Gray C.E., and O'Keane V. Possible up-regulation of 5-hydroxytryptamine receptors in patients with postviral fatigue syndrome. Br Med J 304 (1992) 1566-1567
9. Beck A.T., Ward C.H., Mendelson M., Mock J.E., and Erbaugh J.K. An inventory for measuring depression. Arch Gen Psychiatry 4 (1961) 561-571
10. Blondel-Hill E., and Shafran S.D. Treatment of chronic fatigue syndrome. A review and practical guide. Drugs 46 (1993) 639-651
11. Brunello N., Akiskal H., Boyer P., Gess G.L., Howland R.H., Langer S.Z., et al. Dysthymia: clinical picture, extent of overlap with chronic fatigue syndrome, neuropharmacological considerations, and new therapeutic vistas. J Affect Disord 52 (1999) 275-290
12. Chaganty N.R., and Shults J. On eliminating the asymptotic bias in the quasi-least squares estimate of the correlation parameter. J Stat Plan Inference 76 (1999) 127-144
13. Chalder T., Berelowitz G., Pawlikowska T., Watts L., Wessely S., Wright D., et al. Development of fatigue scale. J Psychosom Res 37 (1993) 147-153
14. Cleare A.J. The neuroendocrinology of chronic fatigue syndrome. Endocr Rev 24 (2003) 236-252
15. Cleare A.J., Bearn J., Allain T., McGregor A., Wessely S., Murray R.M., et al. Contrasting neuroendocrine responses in depression and chronic fatigue syndrome. J Affect Disord 34 (1995) 283-289
16. Deale A., Chalder T., and Wessely S. Commentary on a randomized, double-blind, placebo-controlled trial of fluoxetine and graded exercise for chronic fatigue syndrome. Br J Psychiatry 172 (1998) 491-492 [letter]
17. Dinan T.G., Majeed T., Lavelle E., Scott L.V., Berti C., and Behan P. Blunted serotonin-mediated activation of the hypothalamic-pituitary-adrenal axis in chronic fatigue syndrome. Psychoneuroendocrinology 22 (1997) 261-267
18. Dryson E. Venlafaxine and fibromyalgia. NZMJ 113 (2000) 87
19. First M.B., Spitzer R.L., Gibbon M., and Williams J.B.W. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition With Psychotic Screen (SCID-I/P W/PSY SCREEN) (2001), Biometrics Research, New York State Psychiatric Institute, New York, NY
20. Fisk J.D., Ritvo P.G., Ross L., Haase D.A., Marrie T.J., and Schlech W.F. Measuring the functional impact of fatigue: initial validation of the fatigue impact scale. Clin Infect Dis 18 Suppl 1 (1994) S79-S83
21. Fukuda K., Straus S.E., Hickie I., Sharpe M.C., Dobbins J.G., and Komaroff A. The Chronic Fatigue Syndrome: a comprehensive approach to its definition and study. Ann Intern Med 64 (1994) 951-962
22. Gallagher M. Evaluating and treating comorbid pain and depression. Int Rev Psychiatry 12 (2000) 103-114
23. Gerrity T.R., Papnicolau D.A., Amsterdam J.D., Bingham S., Grossman A., Hedrick T., et al. Immunologic aspects of chronic fatigue syndrome. Neuroimmunomodulation 11 (2004) 351-357
24. Goodnick P.J., and Sandoval R. Psychotropic treatment of CFS and related disorders. J Clin Psychiatry 54 (1998) 13-20
25. Gruber A.J., Hudson J.I., and Pope H.G. The management of treatment-resistant depression in disorders on the interface of psychiatry and medicine. Fibromyalgia, chronic fatigue syndrome, migraine, irritable bowel syndrome, atypical facial pain, and premenstrual dysphoric disorder. Psychiatr Clin North Am 19 (1996) 351-369
26. Guy W. ECDEU Assessment manual for psychopharmacology: publication ADM 76-338 (1976), US Department of Health, Education, and Welfare, Washington, DC 218-222
27. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 23 (1960) 56-62
28. Hartz A.J., Bentler S.E., Brake K.A., and Kelly M.W. The effectiveness of citalopram for idiopathic chronic fatigue. J Clin Psychiatry 64 (2003) 927-935
29. Hayes J.R., Bymaster F., Wong D., Iyenger S., Li D.L., Lee D.H., et al. Duloxetine: a potential new treatment for depressed patients with comorbid pain. Psychosomatics 43 (1992) [Abstract]
30. Henningsen P., Zimmerman T., and Sattel H. Medically unexplained physical symptoms, anxiety, and depression: a meta-analytic review. Psychosom Med 65 (2004) 528-533
31. Hickie I. Nefazadone for patients with chronic fatigue syndrome. ANZ J Psychiatry 33 (1999) 278-280
32. Hickie L., and Scott E. Late-onset depressive disorders: a preventable variant of cerebrovascular disease?. Psychological Med 28 (1998) 1007-1013
33. Hickie I.B., Wilson A.J., Wright J.M., Bennett B.K., Wakefield D., and Lloyd A.R. A randomized, double blind, placebo-controlled trial of moclobemide in patients with chronic fatigue syndrome. J Clin Psychiatry 61 (2000) 643-648
34. Iyengar S., Ahmad L., and Simmons R.M.A. Efficacy of selective serotonin and norepinephrine reuptake inhibitor, duloxetine, in the formalin model of persistent pain. Biol Psychiatry 51 (2002) 222 [Suppl]
35. Jason L.A., King C.P., Frankenberry E.L., Jordan K.M., Tryon W.W., Rademaker F., et al. Chronic fatigue syndrome: assessing symptoms and activity level. J Clin Psychol 55 (1999) 411-424
36. Jason L.A., Taylor R., Agner L., Holden J., Ferrari J.R., Plioplys A.V., et al. Estimating rates of chronic fatigue from a community-based sample: a pilot study. Amer J Commun Psychol 23 (1995) 557-568
37. Kennedy G., Abbot N.C., Spence V., .Underwood C., and Belch J.J.F. The specificity of the CDC-1994 criteria for chronic fatigue syndrome: comparison of health status in three groups of patients who fulfill the criteria. Ann Epidemiol 14 (2004) 95-100
38. Kiser R.S., Cohen H.M., Freedenfeld R.N., Jewell C., and Fuchs P.N. Olanzapine for the treatment of fibromyalgia symptoms. J Pain Symptom Management 22 (2001) 704-708
39. 123I]ADAM in healthy subjects administered different doses of escitalopram or citalopram. Psychopharmacology 188 (2006) 263-272
40. Lynch M.E. Antidepressants as analgesics: a review of randomized, controlled trials. J Psychiatr Neurosci 26 (2001) 30-36
41. Lynch S., and Seth R. Fluoxetine and chronic fatigue syndrome. Lancet 347 (1996) 1771
42. Lynch S., Seth R., and Montgomery S. Antidepressant therapy in the chronic fatigue syndrome. Br J Gen Pract 41 (1991) 339-342
43. Morriss R.K., Ahmed M., Weardon A.J., Mullis R., Strickland P., Appleby L., et al. The role of depression in pain, psychophysiological syndromes and medically unexplained symptoms associated with chronic fatigue syndrome. J Affect Disord 55 (1999) 143-148
44. Natelson B.H., Cheu J., Pareja J., Ellis S.P., Pollicastro T., and Findley T.W. Randomized, double blind, controlled placebo-controlled placebo-phase in trial of low dose phenelzine in the chronic fatigue syndrome. Psychopharmacology 124 (1996) 226-230
45. Natelson B.H., Cheu J., Hill N., Bergen M., Korn L., Denny T., et al. Single-blind, placebo phase-in trial of two escalating doses of selegiline in the chronic fatigue syndrome. Neuropsychobiology 37 (1998) 150-154
46. Neeck G. Neuroendocrine and hormonal perturbations and relations to the serotonergic system in fibromyalgia patients. Scand J Rheumatol 113 (2000) 8-12 [Suppl]
47. O'Malley P.G., Jackson J.L., Santoro J., Tomkins G., Balden E., and Kroenke K. Antidepressant therapy for unexplained symptoms and symptom syndromes. J Fam Pract 48 (1999) 980-990
48. Papanicolaou D.A., Amsterdam J.D., Levine S., McCann S.M., Moore R.C., Newbrand C.H., et al. Neuroendocrine aspects of chronic fatigue syndrome. Neuroimmunomodulation 11 (2004) 65-74
49. Patten S.B., Beck C.A., Kassam A., Williams J.V., Barbui C., and Metz L.M. Long-term medical conditions and major depression: strength of association for specific conditions in the general population. Can J Psychiatry 50 (2005) 195-202
50. Ranjith G. Epidemiology of chronic fatigue syndrome. Occup Med 55 (2005) 13-19
51. Reimherr F.W., Amsterdam J., Fawcett J., Quitkin F.M., Rosenbaum J., Beasley C., et al. Optimal length of continuation therapy: a prospective assessment during fluoxetine long-term treatment. Am J Psychiatry 55 (1998) 1247-1253
52. Rotnizky A., and Jewell N. Hypothesis testing of regression parameters in semiparametric generalized linear models for cluster correlated data. Biometrika 77 (1990) 485-497
53. Ruoff G.E. Depression in the patient with chronic pain. J Fam Pract 43 (1996) S25-S33
54. Scott L.V. The neuroendocrinology of chronic fatigue syndrome: focus on the HPA axis. Funct Neurology 14 (1999) 3-11
55. Sharpe M., Hawton K., Clements A., and Cowen P.J. Increased brain serotonin function in men with chronic fatigue syndrome. Br Med J 315 (1997) 164-165
56. Shults J., and Morrow A. Use of quasi-least squares to adjust for two levels of correlation. Biometrics 58 (2002) 521-530
57. Shults J., Mazurick C., and Landis R. Analysis of repeated bouts of measurements in the framework of generalized estimating equations. Stat Med 25 (2006) 4114-4128
58. Skapinakis P., Lewis G., and Mavreas V. Temporal relations between unexplained fatigue and depression: longitudinal data from an international study in primary care. Psychosom Med 66 (2004) 330-335
59. Solomon L., and Reeves W.C. Factors influencing the diagnosis of chronic fatigue syndrome. Arch Intern Med 164 (2004) 2241-2245
60. Spath M., Wetzel D., and Farber L. Treatment of chronic fatigue syndrome with 5-HT3 receptor antagonists preliminary results. Scand J Rheumatol 29 Suppl 113 (2000) 72-77
61. Stanley N., Fairweather D.B., and Heindmarch I. Effects of fluoxetine and dothiepin on 24-hour activity in depressed patients. Neuropsychobiology 39 (1999) 44-48
62. Sullivan P.F., Pedersen N.L., Jacks A., and Evengard B. Chronic fatigue in a population sample: definitions and heterogeneity. Psychol Med 35 (2005) 1337-1348
63. Taylor K., and Rowbotham M.C. Venlafaxine hydrochloride and chronic pain. West J Med 165 (1996) 147-148
64. Vercoulen J.H., Swanink C.M., Zitman F.G., Vreden S.G., Hoofs M.P., Fennis J.F., et al. Randomized, double-blind, placebo-controlled study of fluoxetine in chronic fatigue syndrome. Lancet 347 (1996) 858-861
65. Wang Y.G., and Carey V.J. Working correlation misspecification, estimation and covariate design: implications for generalized estimating equation performance. Biometrika 90 (2003) 29-41
66. Wearden A.J., Morriss R.K., Mullis R., Strickland P.L., Pearson D.J., Appleby L., et al. Randomised, double-blind, placebo-controlled treatment trial of fluoxetine and graded exercise for chronic fatigue syndrome. Br J Psychiatry 172 (1998) 485-490
67. White P.D., and Cleary K.J. An open study of the efficacy and adverse effects of moclobemide in patients with chronic fatigue syndrome. Int Clin Psychopharmacol 12 (1997) 47-52
68. Whiting P., Bagnall A.M., Sowden A.J., Cornell J.E., Mulrow C.D., and Ramirez G. Interventions for the treatment and management of chronic fatigue syndrome. JAMA 286 (2002) 1360-1368